Efficacy and safety of intravitreal aflibercept injection in wet age-related macular degeneration: outcomes in the Japanese subgroup of the VIEW 2 study

被引：41

作者：

Ogura, Yuichiro ^{[1
]}

Terasaki, Hiroko ^{[2
]}

Gomi, Fumi ^{[3
]}

Yuzawa, Mitsuko ^{[4
]}

Iida, Tomohiro ^{[5
]}

Honda, Miki ^{[6
]}

Nishijo, Koichi ^{[7
]}

Sowade, Olaf ^{[8
]}

Komori, Tetsushi ^{[7
]}

Schmidt-Erfurth, Ursula ^{[9
]}

Simader, Christian ^{[10
]}

Chong, Victor ^{[11
]}

机构：

[1] Nagoya City Univ, Grad Sch Med Sci, Dept Ophthalmol & Visual Sci, Nagoya, Aichi 4678602, Japan

[2] Nagoya Univ, Grad Sch Med, Dept Ophthalmol, Nagoya, Aichi 4648601, Japan

[3] Osaka Univ, Grad Sch Med, Dept Ophthalmol, Osaka, Japan

[4] Nihon Univ, Sch Med, Dept Ophthalmol, Tokyo, Japan

[5] Tokyo Womens Med Univ, Dept Ophthalmol, Tokyo, Japan

[6] Juntendo Univ, Urayasu Hosp, Dept Ophthalmol, Chiba, Japan

[7] Bayer Yakuhin Ltd, Osaka, Japan

[8] Bayer HealthCare Pharmaceut, Berlin, Germany

[9] Med Univ Vienna, Dept Ophthalmol & Optometry, Vienna, Austria

[10] Med Univ Vienna, Vienna Reading Ctr VRC, Vienna, Austria

[11] Univ Oxford, Oxford Eye Hosp, Oxford, England

来源：

BRITISH JOURNAL OF OPHTHALMOLOGY | 2015年 / 99卷 / 01期

关键词：

POLYPOIDAL CHOROIDAL VASCULOPATHY; EXTEND-I; RANIBIZUMAB; NEOVASCULARIZATION; BEVACIZUMAB; POPULATION; PREVALENCE; EYE;

D O I：

10.1136/bjophthalmol-2014-305076

中图分类号：

R77 [眼科学];

学科分类号：

100212 ;

摘要：

Background/aims To evaluate efficacy and safety of intravitreal aflibercept (IVT-AFL) in Japanese patients with wet age-related macular degeneration (wAMD) from the VIEW 2 trial. Methods In this double-masked study, patients were randomised to: 0.5 mg IVT-AFL every 4 weeks (0.5q4); 2 mg IVT-AFL every 4 weeks (2q4); 2 mg IVT-AFL every 8 weeks (2q8) after 3 monthly injections; or 0.5 mg ranibizumab every 4 weeks (Rq4). Main efficacy outcomes included vision maintenance and best-corrected visual acuity (BCVA) at week 52. Results At week 52, all Japanese patients in the IVTAFL groups (n=70) maintained vision, compared with 96% of Japanese patients (n=23/24) treated with ranibizumab. Japanese patients in all treatment groups showed improvement in BCVA after treatment. The Rq4, 2q4 and 2q8 groups experienced similar gains in BCVA from baseline. The 0.5q4 group had higher gains due to an unexpected drop in BCVA between screening and baseline. Central retinal thickness and mean area of choroidal neovascularisation decreased in all treatment groups with similar magnitude. Ocular treatment-emergent adverse events were balanced across treatment groups. Conclusions IVT-AFL was effective and well tolerated in Japanese patients. Outcomes in this population were consistent with those in the overall VIEW 2 population.

引用

页码：92 / 97

页数：6

共 17 条

[1] Towards an understanding of age-related macular disease [J].